Detection of serum IgG autoantibodies to FcεRIα by ELISA in patients with chronic spontaneous urticaria

Jae-Hyuk Jang, Jiyoung Moon, Eun-Mi Yang, Min Sook Ryu, Youngsoo Lee, Young-Min Ye, Hae-Sim Park *

Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, Korea

* hspark@ajou.ac.kr

Abstract

Background

Mast cells are a key effector cell in the pathogenesis of chronic spontaneous urticaria (CSU) and activated by circulating FcεRI-specific IgG as well as IgE. This study evaluated the prevalence of circulating autoantibodies to FcεRIα in the sera of CSU patients.

Methods

Eighty-eight patients with CSU and 76 healthy controls (HCs) were enrolled. To detect circulating autoantibodies (IgG/IgA/IgM) to FcεRIα, ELISA was done using YH35324 (as a solid phase antigen), and its binding specificity was confirmed by the ELISA inhibition test. The antibody levels were presented by the ratio of YH35324-preincubated to mock-preincubated absorbance values. Clinical and autoimmune parameters, including atopy, urticaria activity score (UAS), serum total/free IgE levels, serum antinuclear antibody (ANA) and autologous serum skin test (ASST) results, were assessed. The autoimmune group was defined if CSU patients had positive results to ASST and/or ANA.

Results

The ratio of serum IgG to FcεRIα was significantly lower in CSU patients than in HCs (P<0.05), while no differences were noted in serum levels of IgG to recombinant FcεRIα or IgA/IgM autoantibodies. The autoimmune CSU group had significantly lower ratios of IgG/IgA (not IgM) autoantibodies to FcεRIα than the nonautoimmune CSU group (P<0.05 for each). No significant associations were found between sex, age, atopy, urticaria duration, UAS, or serum total/free IgE levels according to the presence of IgG/IgA/IgM antibodies.

Conclusions

This study confirmed the presence of IgG to FcεRIα in the sera of CSU patients, especially those with the autoimmune phenotype.
Introduction

Chronic spontaneous urticaria (CSU) is defined as the occurrence of wheals, angioedema, or both for more than 6 weeks due to unknown causes [1]. The prevalence rate of CSU was reported at 0.5%-5% in the general population and has been increasing worldwide along with industrialization [2, 3].

Mast cell is a key effector cell, and when activated by various triggers, it releases mediators and cytokines like histamine. Recent guidelines recommend the measurement of serum autoantibody, IgG to thyroid peroxidase (TPO), which is related to not only thyroid diseases but also autoimmune diseases, to evaluate autoimmunity in patients with CSU [1, 4].

Although IgE-mediated mechanism is a major one to activate mast cells, recent studies demonstrate autoimmune-mediated mechanisms in patients with CSU, especially those with more severe phenotypes [5–7]. A type IIb hypersensitivity as an autoantibody-mediated mechanism was first reported in CSU [8]. A-positive result to the autologous serum skin test (ASST) was related to the presence of autoantibodies in CSU [9]. However, the prevalence or role of each autoantibody in CSU has not been fully understood [10, 11]. Among autoantibodies, IgG to FcεRIα has been reported to be a major autoantibody for activating mast cells in CSU patients; however, a recent report has demonstrated a higher prevalence of IgM to FcεRIα (than IgA and IgG antibodies to FcεRIα) in the sera of CSU patients [11].

Regarding the detection method of IgG autoantibody to FcεRIα, several different methods were reported; a standardized method is still unavailable. We could measure serum free IgE using YH35324 (capturing the FcεRIα part of free IgE) in the sera of asthmatics [12] and hypothesized that this YH35324 could capture the FcεRIα binding site of FcεRIα-specific antibodies. Then, we extended ELISA to detect circulating IgG/IgA/IgM autoantibodies to FcεRIα in the sera of CSU patients compared to controls. In the present study, we aimed to evaluate the prevalence of serum IgG/IgA/IgM autoantibodies to FcεRIα in association with clinical/autoimmune parameters in patients with CSU.

Methods

Study subjects

The present study enrolled 88 CSU patients and 76 healthy controls (HCs) from the Department of Allergy and Clinical Immunology, Ajou University Hospital (Suwon, South Korea). Patients who had urticaria symptoms for over 6 weeks without any inducible causes were diagnosed as having CSU. HCs had no history of allergic diseases like urticaria or autoimmune disease.

CSU patients were over 18 years old and had never been exposed to IgE-related biologics. They were allowed to use control medications including antihistamines, except steroids, for 4 weeks prior to the study, and their sera were collected at the diagnosis and stored at −80˚C until estimation. The levels of serum IgG/IgA/IgM autoantibodies to FcεRIα were measured by ELISA with applying YH35324 and compared between CSU patients and HCs. All participants provided written informed consent and agreed to voluntarily participate in the study. This study was approved by the Institutional Review Board of Ajou University Hospital (AJIRB-BMR-SMP-20-435).

The demographic and clinical characteristics of the study subjects were obtained by the investigators. The severity of CSU including disease duration, current medication requirements, and the urticaria activity score (UAS-15) were analyzed. The UAS-15 included the degree of pruritus and the number/size/distribution/duration of wheal over the preceding week at the initial visit. Patients were classified according to the severity of symptoms as
follows: 0, symptom-free; 1 to 5, mild urticaria; 6 to 10, moderate urticaria; and 11 to 15, severe urticaria. Concomitant allergic disease and atopic status were documented.

Skin prick tests (SPT) were performed with 55 common aeroallergens (Bencard, Brentford, UK), which included *Dermatophagoides pteronyssinus*, *D. farinae*, histamine, and a saline negative control. A positive reaction was defined as a wheal of more than 3 mm in diameter or wheal size larger than a positive control (histamine) after 15 minutes. If SPT was not possible, specific IgE antibodies to clinically relevant allergens, including house dust mite (HDM)-specific IgE, were measured. Atopy was defined when SPT showed a positive results or serum allergen specific IgE was elevated ($\geq 0.35$ IU/mL) to at least 1 common environmental allergen. The levels of serum total and specific IgE were measured by ImmunoCAPs (ThermoFisher Scientific, Waltham, MA, USA). Serum free IgE level was measured by ELISA as previously described [12].

**Evaluation of autoimmunity in CSU**

Routine laboratory measurements were taken and included complete blood count, liver enzymes, thyroid stimulating hormone (TSH), and the antinuclear antibody (ANA) screening test. In the cases of abnormal TSH results, thyroid autoantibodies (anti-TPO or anti-TG) were checked. The autologous serum skin test (ASST) was performed to evaluate autoimmune characteristics in CSU patients. The subjects who underwent the ASST had an intradermal injection of 50 $\mu$L of their own sera into their arm. After 30 minutes, the patient’s wheal and flare responses were compared with the responses to normal saline and histamine as controls. An induced wheal larger than 1.5 mm was considered a positive result [13].

**ELISA for the measurement of serum autoantibodies**

The levels of serum autoantibodies to FcεRIα were measured using ELISA by using YH35324 (Yuhan, Seoul, South Korea). This novel YH35324 is based on a human IgG4 Fc domain combined with a human FcεRIα extracellular domain on its Fab chain. As a FcεRIα domain, we speculated that YH35324 could have not only high affinity for serum free IgE but also circulating IgG autoantibodies to FcεRIα. Based on its affinity, we developed a new ELISA using this YH35324 for the measurement of IgG/IgA/IgM autoantibodies to FcεRIα. In brief, the YH35324 in bicarbonate buffer (pH 9.6) was coated at 1 $\mu$g/mL onto each well (a solid phase) overnight at 4°C. After washing 3 times with 0.05% Tween 20 containing phosphate-buffered saline (PBST), the plates were blocked with buffer (10% FBS containing PBST) for 1 hour. Sera from CSU and HCs were pre-incubated for 1 hour with 5 $\mu$g/mL YH35324 or mock (10% FBS containing PBST). Then, 2 kinds of sera (pre-incubated with YH35324 or mock at 1:10 dilution) were loaded onto antigen-coated wells at room temperature for 2.5 hours and washed 5 times with PBST. After washing, each well was incubated with horseradish peroxidase (HRP)-conjugated secondary antibody at room temperature and washed 5 times with PBST.

For the measurement of IgG autoantibodies to FcεRIα, purified serum by using the Gel-IgG-Spin purification kit (ThermoFisher Scientific, Rockford, IL, USA) was incubated, and HRP-conjugated anti-IgG antibody (1:2000, BD Biosciences, Franklin Lakes, NJ, USA) was used as a second antibody, followed by 2 hours of incubation. In the case of IgA and IgM autoantibodies to FcεRIα, sera purification was not applied. HRP-conjugated anti-human IgA and anti-human IgM (1:3000 for IgA, 1:2000 for IgM, SouthernBiotech, Birmingham, AL, USA) were used as second antibodies and incubated for 1.5 hours.

Finally, the plates were incubated with tetramethylbenzidine (TMB) substrate (BD Biosciences) for 20 minutes, followed by stopping the reaction with 2N H$_2$SO$_4$. The absorbance
values were read using an ELISA reader (BioTek, Winooski, VT, USA) at 450 and 570 nm, and the subtracted values were analyzed. All samples were measured 3 times repeatedly, and mean values were analyzed after removing outliers. The coefficient of variation in the reproducibility of ELISA for IgG to FcεRIα was 13.7%. The serum levels of IgG to recombinant FcεRIα were measured simultaneously and compared between patients with CSU and HCs according to the same protocol for the measurement of IgG to FcεRIα except that each well was coated with recombinant soluble FcεRIα (MyBioSource, San Diego, CA, USA) as a solid phase antigen and recombinant soluble FcεRIα was used as an inhibitor instead YH35324.

The levels of IgG/IgA/IgM autoantibody were presented as the ratio of YH35324 preincubated to mock-preincubated values. Reduced levels after the pre-incubation was calculated, and lower ratios represent higher levels of circulating autoantibodies [11].

**ELISA inhibition test**

Competitive ELISA inhibition tests were performed to confirm the binding specificity of YH35324. Sera from patients with CSU were incubated overnight at 4˚C, with increasing amounts (0–1000 μg/mL protein concentration) of YH35324 before use. The pretreated sample was incubated with the YH35324-coated microtiter plate, and ELISA was carried out as previously described. *D. farinae* was used as a nonspecific allergen. The inhibition rate was calculated by the formula: inhibition rate (%) = 100 –(absorbance with inhibitor/absorbance without inhibitor) x100.

**Statistical analysis**

To evaluate the association among 3 autoantibodies and clinical parameters, parametric and non-parametric continuous variables were compared using Student’s *t* test and the Mann-Whitney test. Categorical values were compared Pearson’s Chi-squared test and Fisher’s exact test. Parametric and non-parametric variables were compared among over 2 groups using ANOVA and the Kruskal-Wallis test. If standard deviations were not equal in parametric variables, Welch’s ANOVA test was used. Bonferroni and Dunnett were applied as post hoc tests. Correlation coefficients were calculated by the Pearson method. Cutoff values for the prevalence of circulation autoantibodies to FcεRIα were determined at the 5% percentile ratio of non-autoimmune CSU. All statistical analyses were performed, and graphs were created using R 4.1.0 (R Core Team, 2021), GraphPad Prism Version 9.2.0 for Mac (GraphPad Software, San Diego, CA, USA). Statistical significance was set at *P* less than 0.05 for all tests.

**Results**

**Clinical characteristics of the study subjects**

Table 1 shows the baseline characteristics of patients enrolled compared to HCs. Patients with CSU was younger than HCs (median 37.5 [IQR 25.0–48.0] vs. median 41.0 [IQR 34.0–52.0], *P* = 0.01). No differences were found in sex or atopy prevalence. The mean UAS was 9.2 ± 4.3; positive rates of ASST and ANA were 22.7% and 18.2%, respectively. Both serum total and free IgE levels were significantly higher in CSU patients than in HCs, with significant differences (*P*<0.001 for each). Two patients with CSU had hyperthyroidism and 1 patient with CSU had hypothyroidism. Eight patients with abnormal results of TSH or a history of thyroid disease were positive to at least one thyroid autoantibody (anti-TPO or anti-TG). Patients with positive thyroid autoantibodies did not have any autoantibodies to FcεRIα. S1 Fig showed the correlation between IgG to YH35324 and IgG to recombinant FcεRI. (*Pearson r = 0.41, *P*<0.0001).
The prevalence of serum autoantibodies (IgG/IgA/IgM) to FcεRIα in CSU patients

Fig 1 shows the comparison of serum IgG/IgA/IgM levels to FcεRIα between patients with CSU and HCs. The ratio of IgG to FcεRIα was significantly lower in patients with CSU than in HCs, while no differences were noted in the ratio of IgG to recombinant FcεRIα or IgA/IgM autoantibodies to FcεRIα. The ELISA inhibition test confirmed binding specificity by showing a dose-dependently increasing inhibition rate (%) with serial addition of the YH35324 (0–1000 μg/mL) in the sera of 1 patient with CSU (S2 Fig).

Table 1 summarizes comparisons of clinical parameters with the results of serum IgG/IgA/IgM to FcεRIα. The cutoff value for the positive predictive value of IgG/IgA/IgM to FcεRIα was determined from the results of non-autoimmune CSU and shown as dotted lines (0.65, 0.72, and 0.71, respectively, Figs 1 and 2). The prevalence of serum IgG/IgA/IgM to FcεRIα in CSU were 8.1, 5.8, and 3.4% respectively. No significant differences were noted in demographic findings, clinical parameters (sex, age, atopic status, disease duration, UAS, and serum total/free IgE), or comorbid conditions (allergic rhinitis and asthma) according to the presence of serum IgG/IgA/IgM to FcεRIα. In addition, no differences were noted in peripheral eosinophil or basophil counts between the groups with positive and negative to IgG/IgA/IgM autoantibody. The levels of HDM-specific IgE were higher in the IgG-positive group than in the IgG-negative group (median values of D. pteronyssinus-specific IgE, 18.1 [IQR 1.1–24.9] kU/L vs. 0.1 [IQR 0.1–1.8] kU/L, P<0.05; the median values of D. farinae-specific IgE, 33.9 [IQR 1.3–45.7] kU/L vs. 0.3 [IQR 0.1–2.5] kU/L, P<0.05), while no significant associations were found with atopic status or serum IgE levels between the 2 groups. No differences were found in the results of IgA/IgM autoantibodies as shown in Table 2.

Comparison of IgG to FcεRIα levels with the results of ASST and ANA

When defined if CSU patients had at least 1 positive result to ASST or ANA, the autoimmune CSU group had significantly lower ratio of IgG/IgA to FcεRIα than the non-autoimmune CSU group (the median values of IgG to FcεRIα, 0.73 [IQR 0.68–0.81] vs. 0.78 [IQR 0.72–0.89], P<0.05; the median values of IgA to FcεRIα, 0.93 [IQR 0.87–1.01] vs. 0.99 [IQR 0.93–1.05]) (P<0.05, Fig 2). IgM to FcεRIα showed no difference between the 2 groups. Comparison of

---

Table 1. Clinical characteristics of the study subjects in the cohort.

| Variable                  | CSU (n = 88) | Healthy controls (n = 77) | P value |
|---------------------------|--------------|---------------------------|---------|
| Female, n (%)             | 54 (61.4%)   | 39 (50.6%)                | 0.22    |
| Age (years)               | 37.5 [25.0;48.0] | 41.0 [34.0;52.0]           | 0.01    |
| Atopy, n (%)              | 54 (61.4%)   | 36 (50.0%)                | 0.20    |
| UAS-15                    | 9.2±4.3      | NA                        |         |
| ASST positive, n (%)      | 20 (22.7%)   | NA                        |         |
| ANA positive, n (%)       | 16 (18.2%)   | NA                        |         |
| Serum total IgE (kU/L)    | 135.5 [64.5;312.5] | 50.7 [20.4;110.5]         | <0.001  |
| Serum free IgE (ng/mL)    | 252.9 [99.5;639.8] | 105.9 [23.4;273.5]        | <0.001  |

Non-parametric values are presented as median [IQR] and parametric values or mean ± SD. Categorical values are shown as number (percentage). P values were evaluated by the t test or the Mann Whitney test. CSU, chronic spontaneous urticaria; HCs, healthy controls; UAS, urticaria activity score; ASST, autologous serum skin test; ANA, antinuclear antibody; NA: not available.
serum autoantibodies between the ASST-positive and ASST-negative groups showed no significant difference (S3 Fig).

Discussion

The present study demonstrates the presence of circulating IgG antibody to FcεRIα by the home-made ELISA using purified IgG sera and the YH35324 (capturing the FcεRIα portion of specific IgG to FcεRIα) as the solid phase antigen. The IgG-ELISA inhibition test

Table 2. Clinical characteristics of the patients with chronic spontaneous urticaria (CSU) according to the results of serum autoantibodies to FcεRIα.

| Variables (n = 86) | IgG to FcεRIα | IgA to FcεRIα | IgM to FcεRIα |
|-------------------|---------------|---------------|---------------|
|                   | Negative      | Positive      | Negative      | Positive      | Negative      | Positive      |
|                   | (n = 79, 91.8%) | (n = 7, 8.1%)  | (n = 81, 94.1%) | (n = 5, 5.8%)  | (n = 83, 96.5%) | (n = 3, 3.4%)  |
| Female, n (%)      | 50 (63.3%)     | 3 (42.9%)     | 49 (60.5%)     | 4 (80.0%)     | 51 (61.4%)     | 2 (66.7%)     |
| Age (years)        | 37.0 [25.0;48.5] | 44.0 [38.0;47.0] | 38.0 [27.0;48.0] | 22.0 [22.0;42.0] | 38.0 [25.0;48.0] | 47.0 [41.0;51.5] |
| Angioedema, n (%)  | 38 (48.1%)     | 3 (42.9%)     | 39 (48.1%)     | 2 (40.0%)     | 40 (48.2%)     | 1 (33.3%)     |
| UAS-15             | 10.0 [6.0;13.0] | 7.0 [5.5;11.5] | 10.0 [6.0;13.0] | 9.0 [2.0;12.0] | 10.0 [6.0;13.0] | 15.0 [9.0;15.0] |
| Duration (months)  | 10.0 [2.5;27.0] | 7.0 [4.5;8.0]  | 8.0 [2.5;24.0] | 10.0 [3.0;12.0] | 9.0 [3.0;24.0] | 1.0 [0;6.3]   |
| ASST positive, n (%) | 17 (21.5%)     | 3 (42.9%)     | 19 (23.5%)     | 1 (20.0%)     | 20 (24.1%)     | 0 (0.0%)      |
| ANA positive, n (%) | 13 (16.5%)     | 3 (42.9%)     | 15 (18.5%)     | 1 (20.0%)     | 15 (18.1%)     | 1 (33.3%)     |
| Serum total IgE (kU/L) | 132.0 [59.5;288.0] | 396.0 [179.5;538.0] | 139.0 [61.0;294.0] | 182.0 [93.0;520.0] | 143.0 [65.5;312.5] | 68.0 [37.2;296.5] |
| Serum free IgE (ng/mL) | 254.8 [100.7;555.3] | 788.1 [129.1;797.8] | 254.8 [99.3;611.8] | 311.4 [250.9;781.1] | 266.7 [100.7;639.8] | 163.2 [83.3;478.3] |
| Atopy, n (%)        | 46 (58.2%)     | 7 (100.0%)    | 48 (59.3%)     | 5 (100.0%)    | 52 (62.7%)     | 1 (33.3%)     |
| Der p IgE (kU/L)    | 0.1 [0.1;1.8] * | 18.1 [1.1;24.9] * | 0.2 [0.1;2.4] | 0.5 [0.2;2.0] | 0.2 [0.1;2.0] | 0.2 [0.1;3.4] |
| Der f IgE (kU/L)    | 0.3 [0.1;2.5] * | 33.9 [1.3;45.7] * | 0.4 [0.1;4.3] | 1.4 [0.2;1.8] | 0.4 [0.1;3.9] | 0.2 [0.2;3.0] |
| Eosinophil counts (cells/μL) | 93.5 [57.6;161.8] | 62.4 [44.9;155.1] | 93.5 [57.6;162.8] | 65.0 [36.0;156.0] | 93.5 [55.2;168.9] | 70.4 [35.2;96.0] |
| Basophil counts (cells/μL) | 32.0 [22.8;43.0] | 39.0 [33.5;144.8] | 32.4 [22.8;44.0] | 39.6 [32.5;42.7] | 33.0 [23.7;43.6] | 22.8 [14.6;47.4] |

Non-parametric values are shown as median [IQR] and categorical values are shown as number (percentage). 
P values were evaluated by Pearson’s Chi-squared test or the Mann-Whitney test.

*P<0.05, between patients with negative results and those with positive results to IgG to FcεRIα.
UAS, urticaria activity score; ASST, autologous serum skin test; ANA, antinuclear antibody; Der p, Dermatophagoides pteronyssinus; Der f, Dermatophagoides farinae

https://doi.org/10.1371/journal.pone.0273415.t002
demonstrated the binding specificity with serial additions of YH35324 (up to 88.85% inhibition). In addition, higher levels of serum IgG/IgA to FcεRIα were noted in patients with CSU with autoimmune phenotypes, while serum IgG to recombinant FcεRIα were not detectable in the same serum set of the study subjects. These findings suggest that our ELISA is a reproducible and reliable method to detect serum IgG level to FcεRIα in the sera of various allergic and immunologic diseases, although further replication studies are needed.

For CSU, the autoimmune mechanism plays a major role in activating mast cells [14, 15]. CSU patients with type IIb autoimmunity have serum autoantibodies to FcεRIα or IgE on the surface of mast cells [11, 16]. From the first study on IgG to FcεRIα in patients with CSU to the latest study evaluating the prevalence of IgG, IgA and IgM to FcεRIα in those with CSU, autoimmune CSU has long been studied [11, 17]. However, there are no standardized method to measure serum IgG/IgA/IgM autoantibodies to FcεRIα, and the reference values for determining autoimmunity are not determined.

To define type IIb autoimmune CSU, 3 diagnostic criteria have been recommended: (1) positive ASST, (2) positive basophil histamine release assay and/or basophil activation test, and (3) positive IgG autoantibodies against FcεRIα and/or IgE [4, 7]. CSU patients with positive ASST results present more severe symptoms, including wheals, itching, and systemic manifestations, than those with negative ASST results [7]. However, no difference was noted in this study. The positive rate of the ASST was 22.7% in the present study, which is lower than those of previous studies (34% to 70%) [18, 19]. Autoimmune thyroiditis was reported to be related to the persistent positive result of ASST in patients with CSU independent of urticaria symptoms, questioning the role of ASST in the CSU patients with autoimmune thyroiditis [20]. Further long-term follow-up studies are needed to evaluate its clinical relevance (effects on drug responses or long-term clinical outcomes) in the management of CSU.

The ASST has been increasingly performed and revealed that it is associated with IgG antibodies against the FcεRIα or IgE. The positive reaction in the ASST was reported to confirm...
the presence of autoantibodies in CSU [9]. A previous study showed higher serum IgG to FceRIα estimated by immunoblot assay in CSU patients, especially in those with a positive ASST, although further replication studies are not validated [10]. These findings suggest that IgG to FceRIα may be involved in autoantibody-mediated mechanism of CSU. However, the present study showed no significant difference in IgG to FceRIα between the ASST-positive and ASST-negative group (S3 Fig). The discordance between previous studies and ours in the same ethnicity may be attributed to: (1) differences in the positive rates of ASST found in the study subjects and (2) the different detection methods applied (immune-dot assay vs. ELISA). The sensitivity and specificity between these 2 different assays cannot be comparable [21].

Regarding autoimmune parameters in CSU, ANA has commonly been reported to be present in CSU patients, especially those associated with the autoimmune type IIb [22]. The ANA-positive group is known to be associated with poor responses to antihistamines or omalizumab [23, 24]. The positive ANA rate in CSU patients were 18.2% in the present study, which is consistent with the positive rates (15%-29%) of previous studies [10, 23, 25]. However, no differences were found in UAS or other clinical parameters between the ANA-positive and ANA-negative groups, similar to a previous study [24].

To evaluate autoimmunity in CSU, basophil autoreactivity functional assay is needed, but it is difficult to apply in every patient in the aspects of technical difficulties, cost, and low availability in the real-world practice [26]. Therefore, basophil histamine release assay and/or basophil activation test were not widely performed in real-world study or practice.

The prevalence of IgG autoantibody to FceRIα was reported from 4% to 64% in CSU patients [27]. For IgM and IgA autoantibodies, there has been a study reporting higher prevalence (60% and 57%, respectively) in CSU patients [11]. The present study showed a higher prevalence of IgG to FceRIα in CSU patients than in HCs, but no differences were noted in the prevalence of IgM or IgA autoantibodies to FceRIα between CSU patients and controls. In addition, when they were compared according to autoimmunity, the autoimmune group had a higher prevalence of IgG to FceRIα than the nonautoimmune group, although the prevalence of IgG to FceRIα was 8.1%, which were lower than those of previous studies [11]. The wide range of the prevalence of autoantibodies in CSU has not yet been clearly explained. There are a few explanations of these differences. First, the measurement methods were different among the studies, where western blot analysis, ELISA (with using different antigens/antibodies) or both assays were applied [27]. Further studies are required to confirm the results. Secondly, the discrepancies in autoantibody prevalence may have been attributed to differences in underlying causes and regional differences [1]. Even using the same measurement method, the prevalence rates were variable [10]. Thirdly, the cutoff criteria were different whether they were derived from HCs or other control subjects [10, 11]. The number of the study subjects having high levels of serum autoantibodies to FceRIα was very low, and some of HCs had this autoantibody without any evidence of autoimmune disease or CSU. Therefore, the cutoff values from HCs may have failed to differentiate the autoimmune CSU group from the non-autoimmune CSU group. It is also supported by the fact that the prevalence of disease-related autoantibodies in the disease-free subgroup from the European cohort of autoantibody-related disease was found to be 23.6% [28].

There have been several studies showing that the presence of IgG autoantibodies against FceRIα is linked to more severe symptoms, a poor response to conventional antihistamine treatment, and a slower response to anti-IgE treatment [11, 29, 30]. IgM to FceRIα was reported to have a correlation with peripheral basopenia and eosinopenia [11]. IgA to FceRIα was related to present or past gastrointestinal- or mucosal-associated infections [11]. The present study showed no significant associations between IgG to FceRIα and clinical/severity parameters. Recent studies suggest that, along with mast cells, eosinophils, basophils and other
cells are involved in CSU [31]. Both lesional or non-lesional skin of CSU patients showed a mixed infiltrating cells such as eosinophils and basophils [1, 31–33]. Recruitment of eosinophils into the skin can be mediated by the interactions between mast cells and various mediators. Eosinophil granule proteins from activated eosinophils cause persistent mast cell activation, and IgG-anti-FcεRII/CD23 leads to eosinophil secretion via the low-affinity IgE receptor FcεRII/CD23 on eosinophils and histamine release from basophils, suggesting the role of interactions between mast cells and basophils/eosinophils in the pathogenesis of CSU. When peripheral eosinophil and basophil counts were compared according to the presence of serum IgG to FcεRIα, no differences were found in the present study, indicating that their immune cells are not associated with IgG autoantibody to FcεRIα in CSU.

There are 2 limitations in this study. One is that the operational definition of autoimmune CSU without basophil functional assay may be insufficient to reflect real autoimmunity. Basophil functional assays are the only currently available method to evaluate functional autoantibodies, however they are difficult to conduct in outpatient clinics due to technical difficulties and costs. Both tests for ANA and ASST are poor surrogate markers for a risk of false positivity and a possibility of the co-existence of atopic status [13, 34]. Nonetheless, they are potential alternatives to evaluate autoimmunity which is clinically relevant in CSU patients [13, 23, 35]. The other is that we could not find any clinical significance according to the presence of IgG to FcεRIα as well as IgA/IgM autoantibodies to FcεRIα, which may have been attributed to a lower number of positive responders. Further replication studies in a larger cohort of CSU patients are needed to validate these findings.

In conclusion, we detected higher IgG autoantibody levels to FcεRIα by the ELISA with applying the YH35324 in the sera of CSU patients compared to HCs, which were higher in the autoimmune group, suggesting a possible involvement of circulating autoantibodies against FcεRIα in the autoimmune mechanism of CSU.

Supporting information
S1 Fig. Correlation between log transformed IgG to YH35324 and log transformed IgG to recombinant FcεRI before pretreatment analyzed by Pearson’s correlation. (TIF)

S2 Fig. Competitive ELISA inhibition tests with serial additions of YH35324 and D. farinae extracts (200μg/mL). ELISA, enzyme-linked immunosorbent assay; D. farinae; Dermatophagoides farinae. (TIF)

S3 Fig. Comparison of serum IgG/IgA/IgM levels to FcεRIα between the ASST-positive and ASST-negative group. The results were presented by the IgG ratio of YH35324-pretreated to mock-treated value (A), the IgA ratio of YH35324-pretreated to mock-treated value (B) and the IgM ratio of YH35324-pretreated to mock-treated value (C). ASST, autologous serum skin test; NS, no statistical significance. (TIF)

Author Contributions
Conceptualization: Hae-Sim Park.
Data curation: Jae-Hyuk Jang, Jiyoung Moon, Eun-Mi Yang, Min Sook Ryu, Youngsoo Lee.
Formal analysis: Jae-Hyuk Jang, Eun-Mi Yang.
Investigation: Jiyoung Moon.
Methodology: Eun-Mi Yang, Min Sook Ryu, Youngsoo Lee, Young-Min Ye.
Supervision: Young-Min Ye, Hae-Sim Park.
Visualization: Jae-Hyuk Jang.
Writing – original draft: Jae-Hyuk Jang.
Writing – review & editing: Hae-Sim Park.

References
1. Zuberbier T, Latif AHA, Abuzakouk M, Aquilina S, Asero R, Baker D, et al. The international EAACI/ GA²LEN/EuroGuiDerm/PAAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2021. https://doi.org/10.1111/all.15090 PMID: 34536239.
2. Song WJ, Choi M, Lee DH, Kwon JW, Kim GW, Kim MH, et al. The KAAACI/KDA Evidence-Based Practice Guidelines for Chronic Spontaneous Urticaria in Korean Adults and Children: Part 1. Definition, Methodology and First-line Management. Allergy Asthma Immunol Res. 2020; 12(4):563–78. https://doi.org/10.4168/aair.2020.12.4.563 PMID: 32400125.
3. Fricke J, Avila G, Keller T, Weller K, Lau S, Maurer M, et al. Prevalence of chronic urticaria in children and adults across the globe: Systematic review with meta-analysis. Allergy. 2020; 75(2):423–32. Epub 20191011. https://doi.org/10.1111/all.14037 PMID: 31494963.
4. Kolkhir P, Altrichter S, Asero R, Dashiens A, Ferrer M, Giménez-Arnau A, et al. Autoimmune Diseases Are Linked to Type IIb Autoimmune Chronic Spontaneous Urticaria. Allergy Asthma Immunol Res. 2021; 13(4):545–59. https://doi.org/10.4168/aair.2021.13.4.545 PMID: 34212543.
5. Sabroe R, Seed P, Francis D, Barr R, Black AK, Greaves M. Chronic idiopathic urticaria: comparison of the clinical features of patients with and without anti-FcεRI or anti-IgE autoantibodies. J Am Acad Dermatol. 1999; 40(3):443–50.
6. Caproni M, Volpi W, Giomi B, Cardinali C, Antiga E, Melani L, et al. Chronic idiopathic and chronic autoimmune urticaria: clinical and immunopathological features of 68 subjects. Acta Derm-veneroeol. 2004; 84(4). https://doi.org/10.1080/00015550410026935 PMID: 15339073.
7. Schoepke N, Asero R, Ellrich A, Ferrer M, Gimenez-Arnau A, Grattan CEH, et al. Biomarkers and clinical characteristics of autoimmune chronic spontaneous urticaria: Results of the PURIST Study. Allergy. 2019; 74(12):2427–36. https://doi.org/10.1111/all.13949 PMID: 31228881.
8. Gruber BL, Baeza ML, Marchese MJ, Agnello V, Kaplan AP. Prevalence and Functional Role of Anti-IgE Autoantibodies in Urticarial Syndromes. J Invest Dermatol. 1988; 90(2):213–7. https://doi.org/10.1111/j.1523-1747.ep12462239 PMID: 2445892.
9. Grattan CEH, Boon AP, Eady RAJ, Winkelmann RK. The Pathology of the Autologous Serum Skin Test Response in Chronic Urticaria Resembles IgE-Mediated Late-Phase Reactions. Int Arch Allergy Immunol. 1990; 93(2–3):198–204. https://doi.org/10.1159/000235301 PMID: 2099345.
10. Ulambayar B, Chen Y-H, Ban G-Y, Lee J-H, Jung C-G, Yang E-M, et al. Detection of circulating IgG autoantibody to FcεRia in sera from chronic spontaneous urticaria patients. J Microbiol Immunol Infect. 2020; 53(1):141–7. https://doi.org/10.3389/fimmu.2017.00371 PMID: 29169972.
11. Altrichter S, Zampeli V, Ellrich A, Zhang K, Church MK, Maurer M. IgM and IgA in addition to IgG autoantibodies against FcεRia are frequent and associated with disease markers of chronic spontaneous urticaria. Allergy. 2020. https://doi.org/10.1111/all.14412 PMID: 32446275.
12. Woo SD, Yang EM, Jang J, Lee Y, Shin YS, Ye YM, et al. Serum-free immunoglobulin E: A useful biomarker of atopy and type 2 asthma in adults with asthma. Ann Allergy Asthma Immunol. 2021; 127 (1):109–15.e1. Epub 20210327. https://doi.org/10.1016/j.anai.2021.03.023 PMID: 33785460.
13. Konstantinou GN, Asero R, Maurer M, Sabroe RA, Schmid-Grendelmeier P, Grattan CEH. EAACI/GA²LEN task force consensus report: the autologous serum skin test in urticaria. Allergy. 2009; 64 (9):1256–68. https://doi.org/10.1111/j.1398-9995.2009.02132.x PMID: 19650847.
14. Bracken SJ, Abraham S, MacLeod AS. Autoimmune Theories of Chronic Spontaneous Urticaria. Front Immunol. 2019; 10:627. https://doi.org/10.3389/immu.2019.00627 PMID: 30984191.
15. Ferrer M, Nakazawa K, Kaplan AP. Complement dependence of histamine release in chronic urticaria. J Allergy Clin Immun. 1999; 104(1):169–72. https://doi.org/10.1016/s0091-6749(99)70129-6 PMID: 1040855.
16. Niimi N, Francis DM, Kermani F, O'Donnell BF, Hide M, Kobza-Black A, et al. Dermal Mast Cell Activation by Autoantibodies Against the High Affinity IgE Receptor in Chronic Urticaria. J Invest Dermatol. 1996; 106(5):1001–6. https://doi.org/10.1111/1523-1747.ep12338544 PMID: 8618029.

17. Fiebiger E, Maurer D, Holub H, Reininger B, Hartmann G, Woitschschläger M, et al. Serum IgG autoantibodies directed against the alpha chain of Fc epsilon RI: a selective marker and pathogenetic factor for a distinct subset of chronic urticaria patients? J Clin Invest. 1995; 96(6):2606–12. https://doi.org/10.1172/JCI118325 PMID: 8675625.

18. Baioumy SA, Esawy MM, Shabana MA. Assessment of circulating FcεRIα in Chronic Spontaneous Urticaria patients and its correlation with clinical and immunological variables. Immunobiology. 2018; 223(12):807–11. https://doi.org/10.1016/j.imbio.2018.08.009 PMID: 30144948.

19. Asero R, Tedeschi A, Lorini M, Salimbeni R, Zanoletti T, Miodonna A. Chronic urticaria: novel clinical and serological aspects. Clin Exp Allergy. 2001; 31(7):1105–10. https://doi.org/10.1046/j.1365-2222.2001.01131.x PMID: 11468002.

20. Fusari A, Colangelo C, Bonifazi F, Antonicelli L. The autologous serum skin test in the follow-up of patients with chronic urticaria. Allergy. 2005; 60(2):256–8. https://doi.org/10.1111/j.1398-9995.2005.00673.x PMID: 15647050.

21. Lee M-F, Lin T-M, Liu S-W, Chen Y-H. A Rapid Method of Detecting Autoantibody against FcεRIα in Chronic Spontaneous Urticaria. PLoS ONE. 2014; 9(10):e109565. https://doi.org/10.1371/journal.pone.0109565 PMID: 25332723.

22. Maurer M, Eyerich K, Eyerich S, Ferrer M, Gutermuth J, Hartmann K, et al. Urticaria: Collegium Internationale Allergologicum (CIA) Update 2020. Int Arch Allergy Immunol. 2020; 181(5):321–33. https://doi.org/10.1159/000507218 PMID: 32224621.

23. Ertąc R, Hawro T, Altrichter S, Özyurt K, Erol K, Ertąc ŞK, et al. Antinuclear antibodies are common and linked to poor response to omalizumab treatment in patients with CSU. Allergy. 2019; 75(2):468–70. https://doi.org/10.1111/all.14033 PMID: 31469912.

24. Magen E, Wajtmant D-A, Dickstein Y, Davidovich V, Kahn NR. Clinical-laboratory characteristics of ANA-positive chronic idiopathic urticaria. Allergy Asthma Proc. 2015; 36(2):138–44. https://doi.org/10.2500/aap.2015.36.3829 PMID: 25715242.

25. Coutinho IA, Regateiro FS, Fernandes RA, Pita JS, Gomes R, Coelho C, et al. Refractory chronic urticaria: What Basophil Testing Tells Us About CSU Patients–Results of the CORSA Study. Front Immunol. 2021; 12:742470. https://doi.org/10.3389/fimmu.2021.742470 PMID: 34650565.

26. Marcelino J, Baumann K, Skov PS, Santos MCP, Wyrosdik I, Scheffel J, et al. What Basophil Testing Tells Us About CSU Patients–Results of the CORSA Study. Front Immunol. 2021; 12:742470. https://doi.org/10.3389/fimmu.2021.742470 PMID: 34650565.

27. Kolikhi P, Church MK, Weller K, Metz M, Schmetzer O, Maurer M. Autoimmune chronic spontaneous urticaria: What we know and what we do not know. J Allergy Clin Immunol. 2017; 139(6):1772–81.e1. https://doi.org/10.1016/j.jaci.2016.08.050 PMID: 27777182.

28. Haller-Kikkatalo K, Alnek K, Metspalu R, Zanoletti T, Miadonna A. Chronic urticaria: novel clinical and immunological variables. J Can Soc Allergy Clin Immunol. 2020; 16(1):97. https://doi.org/10.1186/s13223-020-00496-0 PMID: 33292453.

29. Gericke J, Metz M, Ohanyan T, Weller K, Altrichter S, Skov PS, et al. Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria. J Allergy Clin Immunol. 2017; 139(3):1059–61.e1. https://doi.org/10.1016/j.jaci.2016.07.047 PMID: 27893848.

30. Sabroe RA, Fiebiger E, Francis DM, Maurer D, Seed PT, Grattan CEH, et al. Classification of anti-FcεRI and anti-IgE autoantibodies in chronic idiopathic urticaria and correlation with disease severity. J Allergy Clin Immunol. 2002; 110(3):492–9. https://doi.org/10.1067/mai.2002.126792 PMID: 12209101.

31. Giménez-Arnau AM, DeMontjoye L, Asero R, Cugno M, Kullthanan K, Yanase Y, et al. The Pathogenesis of Chronic Spontaneous Urticaria: The Role of Infiltrating Cells. J Allergy Clin Immunol Pract. 2021; 9(6):2195–208. https://doi.org/10.1016/j.jaip.2021.03.033 PMID: 33823918.

32. Kay AB, Ying S, Ardelean E, Mlynek A, Kita H, Clark P, et al. Elevations in vascular markers and eosinophils in chronic spontaneous urticarial weals with low-level persistence in uninvolved skin. Br J Dermatology. 2014; 171(3):505–11. https://doi.org/10.1111/bjd.12991 PMID: 24665899.

33. Min TK, Saini SS. Emerging Therapies in Chronic Spontaneous Urticaria. Allergy Asthma Immuno-Res. 2019; 11(4):470–81. https://doi.org/10.4168/aair.2019.11.4.470 PMID: 31172716.

34. Asero R. Clinical variables of severe chronic spontaneous urticaria from total IgE standpoint: a retrospective study. Eur Ann Allergy Clin Immunol. 2022; 54(1):30–3. Epub 20210208. https://doi.org/10.23822/EurAnnACI.1764-1489.191 PMID: 33555151.
35. Park G-H, Choi J-H, Kim S, Bae Y. The Relation of Autologous Serum Skin Test and Autologous Plasma Skin Test Result with Various Clinical and Laboratory Findings in Patients with Chronic Spontaneous Urticaria. Ann Dermatol. 2020; 32(4):280–8. https://doi.org/10.5021/ad.2020.32.4.280 PMID: 33911755.